Obstructive Lung Diseases |

Once-Daily Tiotropium Respimat Add-on to Medium-Dose Inhaled Corticosteroids Improves Lung Function and Asthma Control in Adult Patients With Moderate Symptomatic Asthma, Independent of Prior Long-Acting _2-Agonist Use FREE TO VIEW

Leon Greos; William Berger; Petra Moroni-Zentgraf; Michael Engel; Reinhold Luehmann; Huib Kerstjens
Author and Funding Information

Colorado Allergy & Asthma Centers, Centennial, CO

Chest. 2015;148(4_MeetingAbstracts):732A. doi:10.1378/chest.2274996
Text Size: A A A
Published online



SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: To determine whether the previously reported improvements in lung function and asthma control following once-daily tiotropium Respimat® (tioR) add-on therapy in adults with moderate symptomatic asthma are influenced by LABA use prior to screening.

METHODS: Two replicate, 24-week, Phase III, randomized, double-blind, parallel-group trials (NCT01172808/NCT01172821) of once-daily tioR 5μg or tioR 2.5μg, twice-daily salmeterol (sal) hydrofluoroalkane metered-dose inhaler 50µg, or placebo (pbo; identical devices in a double-dummy protocol), each as add-on to medium-dose ICS (400-800μg budesonide or equivalent), in adults with moderate symptomatic asthma. Patients were required to have received stable medium-dose ICS±LABA for ≥4 weeks prior to screening; LABAs were not permitted during the 4-week run-in or treatment periods. The three co-primary endpoints at Week 24 were peak and trough FEV1 responses (difference from baseline) in the individual trials and seven-question Asthma Control Questionnaire (ACQ-7) responder rate; post hoc analyses were performed according to patients’ LABA use prior to screening.

RESULTS: 2103 patients were randomized. In the full analysis set, 309, 319, 323, and 320 patients received treatment with a LABA within 3 months before screening in the tioR 5 µg, tioR 2.5µg, sal, and pbo treatment groups, respectively. At Week 24, tioR add-on therapy significantly improved lung function, compared with pbo, independent of prior LABA use. Adjusted mean difference ± standard error for prior and no prior LABA use at screening: peak FEV1, tioR 5µg, 196±25 and 168±31mL, tioR 2.5µg, 220±25 and 229±31mL, sal, 187±25 and 211±31mL (treatment-by-subgroup interaction p=0.8919); trough FEV1, tioR 5µg, 151±27 and 141±33mL, tioR 2.5µg, 177±27 and 186±34mL, sal, 101±27 and 136±33mL (p=0.8992). The proportion of patients classed as ACQ-7 responders (improvement in score ≥0.5) at Week 24 was greater following tioR add-on therapy, compared with pbo, independent of whether patients had (63.4, 61.8, 67.2, and 56.3% for the 5µg, 2.5µg, sal, and pbo treatment groups, respectively) or had not (65.7, 68.9, 65.6, and 60.1%, respectively) previously received LABA therapy.

CONCLUSIONS: Once-daily tioR add-on to medium-dose ICS improves lung function and asthma control, compared with pbo, in adults with moderate symptomatic asthma, independent of patients’ LABA use prior to screening.

CLINICAL IMPLICATIONS: Once-daily tiotropium Respimat® is an efficacious add-on to medium-dose ICS in adults with moderate symptomatic asthma.

DISCLOSURE: Leon Greos: Other: Research from Boehringer Ingelheim Petra Moroni-Zentgraf: Employee: Boehringer Ingelheim Michael Engel: Employee: Boehringer Ingelheim Reinhold Luehmann: Employee: Boehringer Ingelheim Huib Kerstjens: Consultant fee, speaker bureau, advisory committee, etc.: rom Boerhringer an d Pfizer, in relation to the work presented. As consultant, advisory baord member, and as principal investigator and recruiter, Consultant fee, speaker bureau, advisory committee, etc.: From Almirall, to my institution for consultancies, Consultant fee, speaker bureau, advisory committee, etc.: From Novartis, to my institution for consultancies The following authors have nothing to disclose: William Berger

SPIRIVA® (tiotropium) Respimat® is approved for use in asthma in the EU, Japan and many other countries. The indication varies by country. It is currently being reviewed by the US regulatory authorities.




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543